Sheng-Tang Wu
Papers
1
Total Citations
2
H-Index
1
About
Sheng-Tang Wu is a urological researcher whose work centers on improving prostate cancer diagnostics, particularly by accounting for the confounding effects of obesity. His key contribution is the development of body mass weighted prostate-specific antigen (PSA) levels as novel markers to more accurately predict locally advanced prostate cancer following prostatectomy. This innovation addresses a critical gap: obesity can artificially lower PSA concentrations, masking aggressive disease. Wu’s 2024 study on this topic has already garnered early citations, signaling its relevance to refining risk stratification in an increasingly obese patient population. By recalibrating PSA interpretation through body mass index, his research enhances clinical decision-making for high-risk surgical cases. Wu’s work stands at the intersection of oncology, endocrinology, and urology, offering a practical tool to reduce underdiagnosis in overweight men. His focus on personalized biomarker adjustment represents a meaningful step toward more equitable cancer detection, ensuring that body habitus does not compromise the prognostic power of a cornerstone screening test.
Research Focus
Key Achievements
Top Papers
- 1